You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
The funding package earmarks billions for the Public Health and Social Services Emergency Fund and Biomedical Advanced Research and Development Authority.
Issued last week, the guidance said insurers were not required to reimburse such testing, which could impact coverage in schools, workplaces, and other settings.
The Energy and Commerce Committee chairman asked the agency to show Congress all of the state and local plans for COVID-19 testing by July 6.
The experts said that antibody testing cannot indicate an individual's immunity or help with return-to-work schemes but have use for public health agencies.
The lawmakers requested the secretary to direct money from the Public Health and Social Services Emergency Fund to support clinical labs.
The bills would award grants to help public health laboratories purchase high-throughput instruments and to help support diagnostic testing outside of the lab setting.
The total relief package totals $484 billion, including $11 billion for states, localities, territories, tribes, and employers to scale up SARS-CoV-2 testing.
The "roadmap" to getting the economy rolling again calls for the rapid scaling up of testing and a pipeline to develop tests, among other things.